Farnesyl pyrophosphate synthase modulators: a patent review (2006 – 2010)

Bibliography

• Ogura K, Koyama T. Enzymatic aspects of isoprenoid chain elongation. Chem Rev 1998;98:1263-76
   PubMed Web of Science ®Google Scholar
• Liang PH, Ko TP, Wang AH. Structure, mechanism and function of prenyltransferases. Eur J Biochem 2002;269:3339-54
   PubMedGoogle Scholar
• Szkopinska A, Plochocka D. Farnesyl diphosphate synthase; regulation of product specificity. Acta Biochim Pol 2005;52:45-55
   PubMed Web of Science ®Google Scholar
• Sacchettini JC, Poulter CD. Creating isoprenoid diversity. Science 1997;277:1788-9
   PubMed Web of Science ®Google Scholar
• Holstein SA, Hohl RJ. Isoprenoids: remarkable diversity of form and function. Lipids 2004;39:293-309
   PubMed Web of Science ®Google Scholar
• Lynen F, Agranoff BW, Eggerer H, Gamma-gamma-dimethyl-allyl-pyrophosphate and geranyl-pyrophosphate, biological preliminary stages of squalene. 6. biosynthesis of terpenes. Angew Chem Int Ed 1959;71:657-63
   Google Scholar
• Liang PH. Reaction kinetics, catalytic mechanisms, conformational changes, and inhibitor design for prenyltransferases. Biochemistry 2009;48:6562-70
   Google Scholar
• Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 2004;229:567-85
   PubMed Web of Science ®Google Scholar
• Moreno SN, Li ZH. Anti-infectives targeting the isoprenoid pathway of Toxoplasma gondii. Expert Opin Ther Targets 2008;12:253-63
   PubMed Web of Science ®Google Scholar
• Wiemer AJ, Hohl RJ, Wiemer DF. The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anticancer Agents Med Chem 2009;9:526-42
   PubMed Web of Science ®Google Scholar
• Wiemer AJ, Hsiao CH, Wiemer DF. Isoprenoid metabolism as a therapeutic target in gram-negative pathogens. Curr Top Med Chem 2010;10:1858-71
   Google Scholar
• van Beek E, Pieterman E, Cohen L, Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999;264:108-11
   PubMed Web of Science ®Google Scholar
• Kavanagh KL, Guo K, Dunford JE, The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006;103:7829-34
   PubMed Web of Science ®Google Scholar
• Coxon FP, Helfrich MH, Van't Hof R, Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000;15:1467-76
   PubMed Web of Science ®Google Scholar
• Dunford JE, Thompson K, Coxon FP, Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42
   PubMed Web of Science ®Google Scholar
• Hosfield DJ, Zhang Y, Dougan DR, Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J Biol Chem 2004;279:8526-9
   PubMed Web of Science ®Google Scholar
• Rondeau JM, Bitsch F, Bourgier E, Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 2006;1:267-73
   PubMed Web of Science ®Google Scholar
• Russell RGG, Watts NB, Ebetino FH, Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59
   PubMed Web of Science ®Google Scholar
• Roelofs AJ, Thompson K, Ebetino FH, Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2010;16:2950-60
   PubMed Web of Science ®Google Scholar
• Dunford JE. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition. Curr Pharm Des 2010;16:2961-9
   PubMed Web of Science ®Google Scholar
• McKenna CE, Kashemirov BA, Bonaz-Krause PI. Preparation and use of alpha-keto phosphonates. US7462733; 2008
   Google Scholar
• McKenna CE, Kashemirov BA, Sanchez GV. Alpha-hydroxy, alpha-substituted methylenebisphosphonates and phosphonoacetates. US20080200679; 2008
   Google Scholar
• Mustafa DA, Kashemirov BA, McKenna CE. Microwave-assisted synthesis of nitrogen-containing 1-hydroxymethylenebisphosphonate drugs. Tetrahedron Lett 2011;52:2285-7
   Web of Science ®Google Scholar
• Sanders JM, Song Y, Chan JMW, Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases. WO2006039721; 2006
   Google Scholar
• Sanders JM, Song Y, Chan JMW, Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases. US7358361; 2008
   Google Scholar
• Sanders JM, Song Y, Chan JMW, Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases. US7745422; 2010
   Google Scholar
• Sanders JM, Song Y, Chan JMW, Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases. US20100316676; 2010
   Google Scholar
• Martin MB, Arnold W, Heath HT, Nitrogen-containing bisphosphonates as carbocation transition state analogues for isoprenoid biosynthesis. Biochem Biophys Res Commun 1999;263:754-8
   PubMed Web of Science ®Google Scholar
• Ohno K, Mori K, Orita M, Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase. Curr Med Chem 2011;18:220-33
   PubMed Web of Science ®Google Scholar
• Ebetino FH, Roze CN, McKenna CE, Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase. J Organomet Chem 2005;690:2679-87
   Web of Science ®Google Scholar
• Oldfield E, Song Y, Zhang Y, Bisphosphonate compounds and methods. WO2007109585; 2007
   Google Scholar
• Oldfield E, Song Y, Zhang Y, Bisphosphonate compounds and methods. US7687482; 2010
   Google Scholar
• Oldfield E, Zhang Y, Yin F. Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS. WO2008128056; 2008
   Google Scholar
• Oldfield E, Zhang Y. Bisphosphonate compounds and methods with enhanced potency for multiply targets including FPPS, GGPPS, and DPPS. US20080255070; 2008
   Google Scholar
• Zhang YH, Cao R, Yin F, Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J Am Chem Soc 2009;131:5153-62
   PubMed Web of Science ®Google Scholar
• Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994;37:4130-46
   PubMed Web of Science ®Google Scholar
• Sanders JM, Gomez AO, Mao J, 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J Med Chem 2003;46:5171-83
   PubMed Web of Science ®Google Scholar
• Szabo CM, Matsumura Y, Fukura S, Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem 2002;45:2185-96
   PubMed Web of Science ®Google Scholar
• Guo RT, Cao R, Liang PH, Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci USA 2007;104:10022-7
   PubMed Web of Science ®Google Scholar
• Ebetino FH, Mazur A, Lundy MW, 4-azaindole bisphosphonates. WO2010033980; 2010
   Google Scholar
• Ebetino FH, Mazur A, Lundy MW, 5-azaindole bisphosphonates. WO2010033981; 2010
   Google Scholar
• Ebetino FH, Boeckman RK Jr, Song X. (1r,6s)-2-azabicyclo[4.3.0] nonane-8,8-diphosphonic acid and its use in treating or preventing bone disorders, for example, osteoporosis or Paget's disease. WO2008076417; 2008
   Google Scholar
• Ebetino FH, Boeckman RK Jr, Song X. Composition for treating bone disorders. US7781418; 2010
   Google Scholar
• Ebetino FH, Mazur A, Lundy MW, Imidazo[1,2-alpha]pyridinyl bisphosphonates. WO2010033978; 2010
   Google Scholar
• Marma MS, Xia Z, Stewart C, Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J Med Chem 2007;50:5967-75
   PubMed Web of Science ®Google Scholar
• Weiler S, Widler L, Rondeau J-M, C2-C5-alkyl-imidazole bisphosphonates. WO2009068567; 2009
   Google Scholar
• Ebetino FH, Dansereau SM. Bisphosphonate antiresorptive structure-activity relationships. In: Bijvoet O, Fleisch HA, Canfield RE, Russell G. editors. Bisphosphonates on Bones. Elsevier Science B.V; Amsterdam: 1995. p. 139-53
   Google Scholar
• Deprele S, Kashemirov BA, Hogan JM, Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): synthetic, structural, and modeling studies. Bioorg Med Chem Lett 2008;18:2878-82
   Google Scholar
• Dunford JE, Kwaasi AA, Rogers MJ, Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 2008;51:2187-95
   PubMed Web of Science ®Google Scholar
• McKenna CE, Kashemirov BA, Blazewska KM, Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-α]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem 2010;53:3454-64
   PubMed Web of Science ®Google Scholar
• Coxon FP, Helfrich MH, Larijani B, Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 2001;276:48213-22
   PubMed Web of Science ®Google Scholar
• Coxon FP, Ebetino FH, Mules EH, Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 2005;37:349-58
   PubMed Web of Science ®Google Scholar
• Baron RA, Tavare R, Figueiredo AC, Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase. J Biol Chem 2009;284:6861-8
   PubMed Web of Science ®Google Scholar
• Blazewska KM, Ni F, Haiges R, Synthesis, stereochemistry and SAR of a series of minodronate analogues as RGGT inhibitors. Eur J Med Chem; In press; DOI: 10.1016/j.ejmech.2011.04.063
   Google Scholar
• Guo Z, Wu YW, Das D, Structures of RabGGTase-substrate/product complexes provide insights into the evolution of protein prenylation. EMBO J 2008;27:2444-56
   PubMed Web of Science ®Google Scholar
• Tan KT, Guiu-Rozas E, Bon RS, Design, synthesis, and characterization of peptide-based rab geranylgeranyl transferase inhibitors. J Med Chem 2009;52:8025-37
   PubMed Web of Science ®Google Scholar
• Cotesta S, Glickman JF, Jahnke W, Salicyclic acid derivatives being farnesyl pyrophosphate synthase activity inhibitors. WO2010043584; 2010
   Google Scholar
• Amstutz R, Bold G, Cotesta S, Quinolines as inhibitors of farnesyl pyrophosphate synthase. WO2009106586; 2009
   Google Scholar
• Jahnke W, Rondeau JM, Cotesta S, Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. Nat Chem Biol 2010;6:660-6
   PubMed Web of Science ®Google Scholar
• Frost GI. Combination therapy using a soluble hyaloronidase and a bisphosphonate. WO2009128918; 2009
   Google Scholar
• Zanetti D, Cairatti D, Piccinni E, Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof. US7560490; 2009
   Google Scholar
• van Rooijen N, van Nieuwmegen R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res 1984;238:355-8
   PubMed Web of Science ®Google Scholar
• Seiler P, Aichele P, Odermatt B, Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Eur J Immunol 1997;27:2626-33
   Google Scholar
• Chanan-Khan A, Szebeni J, Savay S, Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003;14:1430-7
   PubMed Web of Science ®Google Scholar
• Johnson EM, Johnson ME. Microparticle compositions to modify cancer promoting cells. US20090215729; 2009
   Google Scholar
• Frost GI. Combination therapy using a soluble hyaluronidase and a bisphosphonate. US20090311237; 2009
   Google Scholar
• Ashton P. Implantable formulations of bisphosphonic acids. US20100247607; 2010
   Google Scholar
• Beltz K, Lustenberger P, Petersen H. Pharmaceutical composition with bisphosphonate. WO2009121935; 2009
   Google Scholar
• Beltz K, Lustenberger P, Petersen H. Pharmaceutical composition with bisphosphonate. US20110034418; 2011
   Google Scholar
• Levy N, Cau P, Lopez-Otin C. Combination of an HMG-CoA reductase inhibitor and a farnesyl pyrophosphate synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins. WO2008003864; 2008
   Google Scholar
• Levy N, Cau P, Lopez-Otin C. Use of HMG-CoA reductase and farnesyl pyrophosphate synthase inhibitors for the preparation of a medicine. US20100120720; 2010
   Google Scholar
• Okamura H, Kubo S, Li WV. Gamma.9V.Delta.2 t cell proliferation agent, method for producing activated v.gamma.9v.delta.2 t cells, and uses thereof. US7749760; 2010
   Google Scholar
• McCormack PL, Plosker GL. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer. Drugs 2006;66:711-28
   PubMed Web of Science ®Google Scholar
• Keating GM, Scott LJ. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone. Drugs 2007;67:793-804
   Google Scholar
• Linares GE, Rodriguez JB. Current status and progresses made in malaria chemotherapy. Curr Med Chem 2007;14:289-314
   PubMedGoogle Scholar
• Cau P, Bourgeois P, Bonniol V, Composition and methods used during anti-HIV treatment. US20110046091; 2011
   Google Scholar
• Bonniol V, Bourgeois P, Cau P, Composition and methods used during anti-HIV treatment. WO2009115652; 2009
   Google Scholar
• Bonniol V, Bourgeois P, Cau P, Cosmetic and/or dermatological composition. WO2009112653; 2009
   Google Scholar
• Bae E, Kim J, Kim J. Therapy for Alzheimer's disease. WO2007132292; 2007
   Google Scholar
• Bae E, Kim J, Kim J. Therapy for Alzheimer's disease. WO2007015122; 2007
   Google Scholar
• McKenna CE, Kashemirov BA, Bala JLF. Synthesis of drug conjugates via reaction with epoxide-containing linkers. US20080312440; 2008
   Google Scholar
• Kashemirov BA, Bala JL, Chen X, Fluorescently labeled risedronate and related analogues: “magic linker” synthesis. Bioconjug Chem 2008;19:2308-10
   PubMed Web of Science ®Google Scholar
• Sun S, Blazewska KM, Kashemirov BA, Synthesis and characterization of novel fluorescent nitrogen-containing bisphosphonate imaging probes for bone active drugs. Phosphorus Sulfur Silicon Relat Elem 2011;186:970-1
   PubMed Web of Science ®Google Scholar
• Roelofs AJ, Coxon FP, Ebetino FH, Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010;25:606-16
   PubMed Web of Science ®Google Scholar
• Satchi-Fainaro R, Miller K, Shabat D, Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases. WO2009141823; 2009
   Google Scholar
• Satchi-Fainaro R, Segal E, Kopecek J, A conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions. WO2009141827; 2009
   Google Scholar
• Ebetino FH, Hogan AM, Sun S, The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011;49:20-33
   PubMed Web of Science ®Google Scholar